(Q37013032)

17 August 2017

1 reference

title

Prevention of Type 2 diabetes: fact or fiction? (English)

1 reference

17 August 2017

0 references

Jean-Louis Chiasson

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

18

1 reference

17 August 2017

page(s)

3147-3158

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: the atherosclerosis risk in communities study: 1987-1998

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

The Diabetes Prevention Program (DPP): description of lifestyle intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Diagnostic criteria for diabetes mellitus in Japan--from a report of the Japan Diabetes Society (JDS) Committee on the Diagnosis of Diabetes Mellitus, 1982.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Lowering the criterion for impaired fasting glucose is in order

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

An economic analysis of interventions for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Controlling the diabetes epidemic: how should we screen for undiagnosed diabetes and dysglycaemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

The diabetes risk score: a practical tool to predict type 2 diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Updating the evidence that physical activity is good for health: an epidemiological review 2000-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3147

10.1517/14656566.8.18.3147

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference